Adult Dosing
Acute migraine attacks with or without aura
- 5 mg spray in one nostril x 1
- If headache returns, may repeat dose at least 2 hours after first dose
- Max: 10 mg/24 hrs
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Zolmitriptan should be given only if a clear diagnosis of migraine has been established
- If the patient does not respond to the first dose, reconsider diagnosis of migraine headache before administration of a second dose
- Zolmitriptan is not indicated for prophylaxis of migraine or for use in the management of hemiplegic or basilar migraine
- Safety and effectiveness have not been established for cluster headache
- It may cause coronary vasospasm in patients with history of coronary artery disease (CAD)
- Zolmitriptan should not be given when risk factors for CAD are present. Unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors e.g. hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age. Do not use unless a cardiovascular evaluation establishes that the patient does not have CAD
- Serious adverse cardiac events, including acute MI, have been reported within a few hours following administration
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have occurred with 5-HT1 agonists
- Intermittent long term users should undergo periodic cardiovascular evaluation
- Monitor BP at baseline, cardiovascular evaluation at baseline, then periodically during long-term treatment if risk factors present
- Overuse of acute migraine drugs may lead to worsening of headache. Detoxification may be necessary, including withdrawal of the overused drugs, and treatment of withdrawal symptoms
Cautions: Use cautiously in
- Diabetes mellitus
- Hypertension (due to possibility of unrecognized CAD)
- Hepatic impairment (dose reduction recommended; use alternate dosage form)
- Presence of cardiac risk factors
- Geriatric population due to presence of risk factors for hypertension, hypercholesterolemia, possibility of unrecognized CAD
- Safety and effectiveness in patients over 65 has not been established
Zomig, Zomig nasal spray interacts with :
Pregnancy Category:C
Breastfeeding: Safety unknown; an alternate drug may be preferred, especially while nursing a newborn or preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 July 2010). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Zomig 5 MG SOLN [Bottle] (ASTRAZENECA)
6 mg = $220.99
18 mg = $628.93
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
